Welcome to LookChem.com Sign In|Join Free

CAS

  • or
3-(Benzyloxy)cyclobutanol is a chemical compound characterized by the molecular formula C11H14O2. It is a cyclobutanol derivative featuring a benzyl ether functional group attached to the cyclobutanol ring. This structural composition endows 3-(Benzyloxy)cyclobutanol with a diverse range of applications in organic synthesis and pharmaceutical research, where it serves as a valuable building block for the creation of other organic compounds.

100058-61-5 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 100058-61-5 Structure
  • Basic information

    1. Product Name: 3-(Benzyloxy)cyclobutanol
    2. Synonyms: 3-(Benzyloxy)cyclobutanol;3-(benzyloxy)cyclobutan-1-ol;3-(Benzyloxy)cyclobutanol 97%
    3. CAS NO:100058-61-5
    4. Molecular Formula: C11H14O2
    5. Molecular Weight: 178.22766
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 100058-61-5.mol
  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: /
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: Sealed in dry,Room Temperature
    8. Solubility: N/A
    9. CAS DataBase Reference: 3-(Benzyloxy)cyclobutanol(CAS DataBase Reference)
    10. NIST Chemistry Reference: 3-(Benzyloxy)cyclobutanol(100058-61-5)
    11. EPA Substance Registry System: 3-(Benzyloxy)cyclobutanol(100058-61-5)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 100058-61-5(Hazardous Substances Data)

100058-61-5 Usage

Uses

Used in Organic Synthesis:
3-(Benzyloxy)cyclobutanol is utilized as a building block in organic synthesis for the development of various organic compounds. Its unique structure, which includes a cyclobutanol ring and a benzyl ether group, provides a versatile platform for the synthesis of complex organic molecules.
Used in Pharmaceutical Research:
In pharmaceutical research, 3-(Benzyloxy)cyclobutanol is employed as a reagent in the preparation of biologically active molecules. Its presence in the synthesis process can contribute to the discovery and development of new drugs with potential therapeutic applications.
Used in Drug Development:
3-(Benzyloxy)cyclobutanol is used as a precursor in the synthesis of natural products with potential medicinal properties. Its structural features make it a key component in the development of new drugs and agrochemicals, enhancing the range of compounds available for medical and agricultural use.
Used in Agrochemical Development:
3-(Benzyloxy)cyclobutanol also plays a role in the development of agrochemicals, where it can be used to create compounds with applications in agriculture, such as pesticides or herbicides, contributing to the advancement of crop protection strategies.

Check Digit Verification of cas no

The CAS Registry Mumber 100058-61-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,0,0,5 and 8 respectively; the second part has 2 digits, 6 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 100058-61:
(8*1)+(7*0)+(6*0)+(5*0)+(4*5)+(3*8)+(2*6)+(1*1)=65
65 % 10 = 5
So 100058-61-5 is a valid CAS Registry Number.

100058-61-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name 3-(phenylmethoxy)cyclobutan-1-ol

1.2 Other means of identification

Product number -
Other names 3-(Phenylmethoxy)cyclobutanol

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:100058-61-5 SDS

100058-61-5Relevant articles and documents

5-Alkyl-2-urea-Substituted Pyridines: Identification of Efficacious Glucokinase Activators with Improved Properties

Kohn, Todd J.,Du, Xiaohui,Lai, Sujen,Xiong, Yumei,Komorowski, Renee,Veniant, Murielle,Fu, Zice,Jiao, Xianyun,Pattaropong, Vatee,Chow, David,Cardozo, Mario,Jin, Lixia,Conn, Marion,DeWolf, Walter E.,Kraser, Christopher F.,Hinklin, Ronald J.,Boys, Mark L.,Medina, Julio C.,Houze, Jonathan,Dransfield, Paul,Coward, Peter

, p. 666 - 670 (2016)

Two 1-(4-aryl-5-alkyl-pyridin-2-yl)-3-methylurea glucokinase activators were identified with robust in vivo efficacy. These two compounds possessed higher solubilities than the previously identified triaryl compounds (i.e., AM-2394). Structure-activity re

Discovery of novel selective GPR120 agonists with potent anti-diabetic activity by hybrid design

Sheng, Ren,Yang, Liu,Zhang, Yanchun,Xing, Enming,Shi, Rui,Wen, Xiaoan,Wang, Heyao,Sun, Hongbin

, p. 2599 - 2604 (2018)

GPR120 is an attractive target for the treatment of type 2 diabetes. In this study, a series of biphenyl derivatives were designed, synthesized by hybrid design. The selected compound 6a exhibited potent GPR120 agonist activity (EC50 = 93 nM) and high selectivity over GPR40. The results of oral glucose tolerance test (OGTT) demonstrated that 6a exhibited significant glucose-lowering effect in glucose-loaded ICR male mice. Analysis of the structure–activity relationship is also presented. Compound 6a deserves further biological evaluation and structural modifications.

COMPOUNDS AND USES THEREOF

-

Page/Page column 356, (2021/08/06)

The present disclosure features compounds useful for the treatment of BAF complex-related disorders.

COMPOUND SERVING AS IRAK INHIBITOR

-

Paragraph 0221-0222, (2021/10/07)

The present disclosure relates a compound as an IRAK inhibitor. Specifically, the present disclosure provides a compound of formula I, or a cis-trans isomer, an optical isomer, a racemate, a pharmaceutically acceptable salt, a prodrug, a deuterated derivative thereof, a hydrate or a solvate thereof. The compounds disclosed herein have potent inhibitory effects on IRAK and thus have therapeutic effect on IRAK-related diseases.

MERTK DEGRADERS AND USES THEREOF

-

Paragraph 00827, (2020/01/31)

The present invention provides compounds, compositions thereof, and methods of using the same.

THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS

-

Paragraph 0550, (2020/12/11)

Disclosed herein are certain thiadiazolyl derivatives Formula (I): that inhibit DNA Polymerase Theta (Polθ) activity, in particular inhibit Polθ activity by inhibiting ATP dependent helicase domain activity of Polθ. Also, disclosed are pharmaceutical compositions comprising such compounds and methods of treating and/or preventing diseases treatable by inhibition of Polθ such as cancer, including homologous recombination (HR) deficient cancers.

CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS

-

Page/Page column 395, (2019/10/23)

The present invention provides cereblon binders for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway along with their use in therapeutic applications as described herein.

PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS

-

Page/Page column 125, (2019/01/10)

Compounds of Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII), and methods of use as lnterleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.

Synthesis of Electron-Deficient Heteroaromatic 1,3-Substituted Cyclobutyls via Zinc Insertion/Negishi Coupling Sequence under Batch and Automated Flow Conditions

Tissot, Matthieu,Body, Nathalie,Petit, Sylvain,Claessens, Jehan,Genicot, Christophe,Pasau, Patrick

supporting information, p. 8022 - 8025 (2019/01/04)

Synthesis of 1,3-substituted cyclobutyls enabled by zinc insertion into functionalized iodocyclobutyl derivatives followed by Negishi coupling with halo-heteroaromatics is reported. Two distinct sets of conditions were developed; the first involved a two-step batch protocol using activated Rieke zinc, and the second involved a multistep continuous flow process. Both methods showed complementarity and allowed for rapid access to these medicinally relevant motifs, the possibility of scaling up, and automation for library synthesis.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 100058-61-5